Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Immune globulin - Biotest

Next Previous
Drug Profile

Immune globulin - Biotest

Alternative Names: BT-595; Human normal immunoglobulin - Biotest; Yimmugo

Latest Information Update: 14 Apr 2026

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Biotest Pharmaceuticals
  • Developer Biotest Pharmaceuticals; Pharma Pharmaceutical Industries
  • Class Anti-infectives; Anti-inflammatories; Antiarrhythmics; Antibacterials; Antidementias; Antifibrotics; Antivirals; Eye disorder therapies; Immunoglobulins; Immunoproteins; Polyethylene glycols; Serum globulins; Skin disorder therapies; Vascular disorder therapies
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Marketed Idiopathic thrombocytopenic purpura; Primary immunodeficiency diseases

Most Recent Events

  • 06 Nov 2025 Pharmacodynamics and pharmacokinetics data from a phase III trial in Immunodeficiency disorders presented at the 2025 Annual Scientific Meeting of the American College of Allergy, Asthma & Immunology (ACAAI-2025)
  • 09 Oct 2025 Launched for Primary immunodeficiency diseases (In adolescents, In children, In the elderly, In adults) in USA (IV)
  • 01 Jul 2024 Biotest plans to launch Immune globulin in USA in Q1 2025

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top